Key Points – HUTCHMED remained profitable in H1 2026, reporting $162 million in oncology revenue, up 23% year over year, and $16 million in net income.
The company ended the period with $1.4 billion in cash and maintained full-year oncology revenue guidance of $330 million to $415 million. – Commercial growth was led by China sales of ELUNATE and SULANDA, both up more than 40%, while global FRUZAQLA in-market sales rose 40% and sales outside the U.S. increased 70%
Management said FRUZAQLA’s international growth runway remains significant because reimbursement coverage is about 50%. – The company advanced its pipeline with upcoming savolitinib data readouts, positive Phase III results for sovleplenib in warm autoimmune hemolytic anemia, and the launch of a Phase III trial for HMPL-760 in diffuse large B-cell lymphoma. HUTCHMED is also holding discussions with multinational companies about potential collaborations for its ATTC programs. HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported results.
The company maintained its full-year oncology revenue guidance of $330 million to $415 million and said it remained profitable during the period. Acting CEO and CFO Johnny Cheng said the company recorded strong China product sales, particularly for ELUNATE and SULANDA, both of which grew by more than 40%. He also cited strong global in-market sales for FRUZAQLA, with markets outside the U.S. increasing 70% following geographic expansion.